Clinical Trial Update: Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ivabradine for cardiac autonomic dysfunction related to thoracic radiation therapy; study terminated with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autonomic Dysfunction
• Cancer Survivorship
• Lymphoma

Drugs mentioned

• IVABRADINE

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Lymphoma, Autonomic Imbalance | Phase 2 | Status: TERMINATED | Results posted: 2022-02-10